JANX-007

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameJANX-007
Drug Alias NamePSMA-TRACTrPSMA TRACTr - Janux Therapeutics/Merck & CoProstate specific membrane antigen tumour activated T-cell engager therapy - Janux Therapeutics/Merck & CoProstate specific membrane antigen tumour activated T-cell engager therapyJANX-007 +[6] 
ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > T cell engagers
Mechanisms of ActionAnti-PSMAAnti-CD3
TargetsProstate-Specific Membrane AntigenT cell surface glycoprotein CD3
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesJanux Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesJanux Therapeutics IncMerck KGaA, Darmstadt, Germany
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A